Page last updated: 2024-11-05

n-deacetyl-n-formylcolchicine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-deacetyl-N-formylcolchicine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23890
CHEMBL ID85710
CHEBI ID138826
SCHEMBL ID4069971
MeSH IDM0216186

Synonyms (43)

Synonym
n-formyl-deacetylcolchicine
CHEMBL85710
n-formyldesacetylcolchicine
formamide, n-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-, (s)-
n-deacetyl-n-formylcolchicine
n-formyldeacetylcolchicine
nsc 403142
formyldescaetylcolchicine, n-
brn 2824080
gloriosine
colchicine, n-deacetyl-n-formyl-
nsc-403142
formyldesacetylcolchicine, n-
7411-12-3
formamide,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)-, (s)-
NSC403142 ,
NCGC00163534-01
CHEBI:138826
n-[(7s)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]formamide
NCGC00163534-02
C19981
4-14-00-00942 (beilstein handbook reference)
u02803h7oj ,
unii-u02803h7oj
n-deacetyl-n-formyl colchicine
n-formyl-n-deacetylcolchicine
AKOS017343603
CCG-208385
formamide,n-[(7s)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]-
SCHEMBL4069971
n-[(7s)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5h-benzo[d]heptalen-7-yl]formamide
gtpl7526
DTXSID80225057
n-((7s)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)formamide
formamide, n-((7s)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-
colchicine impurity a [ep impurity]
mfcd00468038
sr-05000002280
SR-05000002280-2
gloriosine (n-deacetyl-n-formyl-colchicin)
Q9268800
?gloriosine
PD047744

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"A method for extracting LD50 values from antitumor test data is described."( Toxicity quantitative structure--activity relationships of colchicines.
Beisler, JA; Neiman, Z; Quinn, FR, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyclic ketone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency12.58930.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID139239Logarithm of toxic activity (1/lethal dose) in mice bearing P388 leukemia on chronic regimen (Q 1-9)1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Toxicity quantitative structure--activity relationships of colchicines.
AID23461Partition coefficient (logP)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Quantitative structure-activity relationships of colchicines against P388 leukemia in mice.
AID134556Compound was tested for toxicity in non tumored mice1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Toxicity quantitative structure--activity relationships of colchicines.
AID1668781Effect on autophagosome in Parkinson's disease patient derived human ONS cells assessed as LC3b parameters at 10 uM after 24 hrs by anti-LC3b 1/335 staining based fluorescence assay2020Journal of natural products, 05-22, Volume: 83, Issue:5
A Grand Challenge. 3. Unbiased Phenotypic Function of Metabolites from Australia Plants
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1668778Cytotoxicity against Parkinson's disease patient derived human ONS cells assessed as effect on cell morphology parameters at 10 uM after 24 hrs by DAPI staining based fluorescence assay2020Journal of natural products, 05-22, Volume: 83, Issue:5
A Grand Challenge. 3. Unbiased Phenotypic Function of Metabolites from Australia Plants
AID154376Antitumor activity against murine lymphocytic leukemia P388 cells1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Quantitative structure-activity relationships of colchicines against P388 leukemia in mice.
AID1668780Effect on mitochondria parameters in Parkinson's disease patient derived human ONS cells at 10 uM after 24 hrs by MitoTracker Orange CMTMRos staining based fluorescence assay2020Journal of natural products, 05-22, Volume: 83, Issue:5
A Grand Challenge. 3. Unbiased Phenotypic Function of Metabolites from Australia Plants
AID23448Partition coefficient (logP)1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Toxicity quantitative structure--activity relationships of colchicines.
AID1668779Effect on alpha-tublin parameters in Parkinson's disease patient derived human ONS cells at 10 uM after 24 hrs by anti-alphatubulin staining based fluorescence assay2020Journal of natural products, 05-22, Volume: 83, Issue:5
A Grand Challenge. 3. Unbiased Phenotypic Function of Metabolites from Australia Plants
AID134555Compound was tested for toxicity in P388 tumored mice1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Toxicity quantitative structure--activity relationships of colchicines.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1668777Cytotoxicity against Parkinson's disease patient derived human ONS cells assessed as effect on nucleus morphology parameters at 10 uM after 24 hrs by DAPI staining based fluorescence assay2020Journal of natural products, 05-22, Volume: 83, Issue:5
A Grand Challenge. 3. Unbiased Phenotypic Function of Metabolites from Australia Plants
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1345665Human bromodomain containing 4 (Bromodomain kinase (BRDK) family)2013Angewandte Chemie (International ed. in English), Dec-23, Volume: 52, Issue:52
4-Acyl pyrroles: mimicking acetylated lysines in histone code reading.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.24 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]